Endpoints News

Endpoints News is an independent journalism company covering the most critical developments for leaders across the biopharma world. Founded by John Carroll and Arsalan Arif in 2016, Endpoints has grown to over 30 full-time staff with a global team of writers and media pros. The site provides daily news coverage on regulatory agencies, clinical trials, partnerships, pipelines, and people behind the biopharma industry. With a focus on accuracy and depth, Endpoints News aims to keep its readers informed about the latest developments in the industry.

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site is known for its high journalistic standards. It strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. It has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

85%

Examples:

  • Amgen plans to rapidly move forward with a final-stage program for MariTide while discontinuing development of its experimental weight loss pill.
  • MariTide is in an ongoing midstage trial and initial data will be released later this year, while Amgen plans a late-stage trial for MariTide in obesity and a stage two trial in diabetes treatment.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

  • Amgen Shifts Focus to Promising Obesity Drug MariTide, Discontinues Development of AMG-786

    Amgen Shifts Focus to Promising Obesity Drug MariTide, Discontinues Development of AMG-786

    Broke On: Friday, 03 May 2024 Amgen, a California-based biotech company, announced its focus on MariTide, an injectable obesity drug in Phase 2 trials with promising interim results. Patients lost an average of 14.5% body weight in 12 weeks according to phase one data. Amgen plans late-stage studies and expansion of manufacturing capacity for this differentiated obesity treatment.

  • Recent Studies Highlight New Approaches and Insights in Blood Pressure Management

    Broke On: Tuesday, 14 November 2023 Chronic insufficient sleep can increase insulin resistance in healthy women, particularly postmenopausal women. Alnylam Pharmaceuticals has developed an RNA interference treatment, zilebesiran, which has shown to reduce blood pressure for six months with one to two doses in a mid-stage clinical trial. Reducing sodium intake can help lower blood pressure as effectively as medication. A systolic blood pressure treatment target under 120 mm Hg improves outcomes and saves lives compared with a threshold of 140 mm Hg for higher risk patients with hypertension.